Ibuprofen vs Naproxen: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Ibuprofen non-selectively inhibits COX-1 and COX-2, suppressing protective prostaglandin synthesis in the gastric mucosa. Without this prostaglandin shield, stomach acid erodes the mucosal lining, causing microscopic bleeding that depletes iron over time and impairing folate absorption through the damaged intestinal epithelium. CTD documents gene interactions affecting prostaglandin synthesis enzymes and folate transport proteins. Vitamin C is consumed at the sites of mucosal inflammation as an antioxidant, further depleting circulating levels.
Ibuprofen achieves 80% oral bioavailability with an extremely short 1.6-hour half-life, requiring dosing every 4–6 hours for sustained pain relief — each dose creating a fresh GI mucosal insult.
- ✓Shortest NSAID half-life means fastest clearance — GI mucosa gets recovery time between doses
- ✓Available OTC in low doses (200 mg) — accessible for short-term self-management
- ✓Extensive safety data spanning decades of global OTC use and clinical trials
- ✓Lower cardiovascular risk than naproxen at recommended OTC doses for short-term use
- ✗Every-4–6-hour dosing creates 3–4 daily GI mucosal insults versus naproxen's 1–2
- ✗Short duration makes it impractical for chronic pain requiring round-the-clock coverage
- ✗Higher total daily pill burden increases non-adherence and inconsistent depletion patterns
- ✗At prescription doses (800 mg TID), GI bleeding risk approaches naproxen's chronic exposure
Short-term pain relief (headaches, menstrual cramps, acute injuries) where the brief duration limits cumulative GI mucosal damage and nutrient depletion.
Naproxen inhibits both COX-1 and COX-2 with the same mucosal damage mechanism as ibuprofen, but its dramatically longer half-life means the gastric mucosa is under sustained prostaglandin suppression for 12+ hours per dose. This prolonged exposure creates a larger cumulative mucosal erosion window, potentially causing more microscopic bleeding (iron loss), more sustained folate malabsorption, and more continuous vitamin C consumption at inflammatory sites. CTD documents broader gene interactions including effects on platelet aggregation pathways.
Naproxen achieves 99% bioavailability — nearly complete absorption — with a 14.5-hour half-life allowing twice-daily dosing. The near-perfect absorption means virtually every milligram reaches systemic circulation and the GI mucosa.
- ✓14.5-hour half-life provides genuine round-the-clock pain relief with twice-daily dosing
- ✓99% bioavailability ensures consistent, predictable therapeutic levels and predictable depletion
- ✓Lowest cardiovascular risk among NSAIDs — the preferred NSAID for patients with heart disease
- ✓Fewer daily doses (2 vs 3–4) may reduce total GI irritation events despite longer per-dose exposure
- ✗FAERS death-associated rate of 17.4% versus ibuprofen's 5.0% — partly reflecting use in sicker chronic pain populations
- ✗14.5-hour half-life means sustained, uninterrupted GI mucosal exposure per dose
- ✗99% bioavailability leaves no portion unabsorbed — maximum drug exposure to GI tissue
- ✗Chronic use for arthritis creates the most sustained cumulative iron loss through microscopic bleeding
Chronic inflammatory conditions (arthritis, tendinitis) requiring sustained pain relief, especially in patients with cardiovascular risk factors where naproxen's cardiac safety advantage matters.
Feature Comparison
| Feature | Ibuprofen | Naproxen |
|---|---|---|
| Drug Class | NSAID (propionic acid) | NSAID (propionic acid) |
| Nutrients Depleted | 3 — folate, iron, vitamin C | 3 — folate, iron, vitamin C |
| Half-Life | 1.6 hours | 14.5 hours (9x longer) |
| Bioavailability | 80% | 99% |
| Dosing Frequency | Every 4–6 hours (3–4x daily) | Every 12 hours (twice daily) |
| FAERS Death Rate | 5.0% | 17.4% |
| CV Risk Profile | Moderate (dose-dependent) | Lowest among NSAIDs |
| GI Exposure Pattern | Intermittent (short pulses) | Sustained (12h+ continuous) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both NSAIDs deplete the same three nutrients through identical COX-mediated GI damage — your folate, iron, and vitamin C supplementation protocol is the same. The pharmacokinetic profiles create a genuine trade-off. Ibuprofen's 1.6-hour half-life means faster mucosal recovery between doses, but 3–4 daily doses create more frequent insult events. Naproxen's 14.5-hour half-life means fewer doses but sustained mucosal exposure per dose. For short-term use, ibuprofen's rapid clearance limits cumulative damage. For chronic use, naproxen's cardiovascular safety advantage — the lowest CV risk of any NSAID — makes it the preferred choice despite its longer GI exposure. FAERS shows naproxen's 17.4% death-associated rate versus ibuprofen's 5.0%, but this reflects naproxen's chronic pain population, not inherent toxicity. Either way, iron monitoring via ferritin is essential for anyone on regular NSAID therapy.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): gene interactions for both drugs affecting prostaglandin synthesis and folate transport pathways
- [2]ChEMBL bioactivity database: clinical trial data for both NSAIDs across acute and chronic pain indications
- [3]FAERS (FDA Adverse Event Reporting System): ibuprofen 5.0% death-associated rate; naproxen 17.4% death-associated rate reflecting different prescribing populations
- [4]PubMed PMID 28925781 — Bhatt DL et al. NSAID use and risk of cardiovascular events. Lancet. 2017;390(10090):135-136
- [5]PubMed PMID 27461180 — Sostres C et al. Nonsteroidal anti-inflammatory drugs and upper and lower GI mucosal damage. Arthritis Research & Therapy. 2013;15(Suppl 3):S1
Check your medications
Check Free →